A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer

Overview

The purpose of this study is to evaluate the efficacy of anti-emetic drug Aprepitant upon the combination chemotherapy of nedaplatin and docetaxel for non-small cell lung cancer (NSCLC).

Full Title of Study: “A Study to Evaluate the Efficacy of Anti-emetic Drug Aprepitant Upon the Combination Chemotherapy of Nedaplatin and Docetaxel for Non-small Cell Lung Cancer”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Other
  • Study Primary Completion Date: March 2015

Detailed Description

The purpose of this study is to evaluate the efficacy of anti-emetic drug Aprepitant upon the combination chemotherapy of nedaplatin and docetaxel for non-small cell lung cancer (NSCLC). The incidence and grade of chemotherapy-induced nausea and vomit (CINV) will be assessed in patients receiving Aprepitant for the prevention of CINV upon the combination chemotherapy of nedaplatin and docetaxel for NSCLC. These data will be compared with those surveyed retrospectively in patients who had received the combination chemotherapy with anti-emetic agents except Aprepitant.

Interventions

  • Drug: Aprepitant
    • The incidence and grade of chemotherapy-induced nausea and vomit (CINV) will be assessed in patients receiving Aprepitant for the prevention of CINV upon the combination chemotherapy of nedaplatin and docetaxel for NSCLC. These data will be compared with those surveyed retrospectively in patients who had received the combination chemotherapy with anti-emetic agents but Aprepitant.

Clinical Trial Outcome Measures

Primary Measures

  • Evaluation of anti-emetic drug efficacy: Incidence and grade of nausea/vomiting
    • Time Frame: Fifteen days after beginning of each cycle of chemotherapy

Secondary Measures

  • Influence on clinical outcome: Survival
    • Time Frame: Participants will be followed for 3 years after the last treatment

Participating in This Clinical Trial

Inclusion Criteria

1. Patients who receive the combination chemotherapy of nedaplatin and docetaxel as a treatment or an adjuvant therapy for non-small cell lung cancer. 2. ECOG performance status 0-1. 3. Aged 20-79 years old. 4. Laboratory values as follows 4000/mm3 < WBC < 12000/mm3, neutrophil count > 2000/mm3, platelet count > 100000/mm3, hemoglobin > 9.5g/dL, asparate transaminase < 2.5 X cutoff value, alanine transaminase < 2.5 X cutoff value, total bilirubin < 1.5g/dL, Serum creatinine < cutoff value, PaO2 > 60 Torr. 5. Able and willing to give valid written informed consent. Exclusion Criteria:

1. Allergy against polysorbert 80 or platinum-containing drugs. 2. Severe complications (i.e. ischemic heart diseases required treatment, arrhythmia, myocardial infarction within 6 months, liver cirrhosis, uncontrolled diabetes, and hemorrhagic tendency). 3. Active and uncontrolled infectious disease. 4. Massive pleural or pericardial effusion. 5. Other malignancy requiring treatment. 6. Active interstitial pneumonitis or its past historyBreastfeeding and Pregnancy (woman of child bearing potential) 7. Peripheral nerve disorder. 8. Pregnant or lactating women. 9. Concurrent administration of pimozide. 10. Decision of unsuitableness by principal investigator or physician-in-charge

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 79 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Shiga University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Yataro Daigo, Professor – Shiga University
  • Overall Official(s)
    • Yataro Daigo, MD, PhD, Principal Investigator, Shiga University of Medical Science

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.